Fungi inclusive of molds, mildew and yeast are types of parasites which infect various parts of the body such as the digestive tract, skin, genitals, lungs, liver and other body tissues. Systemic fungal infections are the ones in which fungi enter the bloodstream and cause more serious conditions. It is caused either by invasive organisms common in a specific geographic area or an opportunistic organism that attacks immune-suppressed individuals. These infections cause more serious effects in the immune-compromised individuals.
The different types of commonly occurring systemic fungal infections include Candidiasis, Aspergillosis, Blastomycosis, Coccidioidomycosis and Histoplasmosis. The possibility of systemic fungal infections is high in the case of oncology patients, immune-compromised patients, patients receiving chemotherapy with severe systemic illness or burns, and in patients on prolonged broad spectrum antibiotic therapies. These infections commonly cause death in patients dealing with leukemia. Systemic fungal infections can be diagnosed based on conventional means and modern means. Conventional means of diagnosis include the screening of patients using blood cultures which might delay the antifungal therapy. On the other hand, modern tests advocated for the diagnosis of systemic fungal infections are sandwich ELISA and polymerase chain reaction (PCR). These tests are advantageous and more reliable than the conventional ones.
Download exclusive Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=2158
Antifungal drugs are administered to curb these infections and further prevent the development of fungal infections in the immune-compromised individuals. Systemic fungal infections need aggressive treatment measures either with the use of intravenous or oral drugs. The major classes of drugs used for treating fungal infections include azoles, polyenes and echinocandins. Systemic fungal infections therapeutics market exhibits commendable growth potential due to increasing incidence of these infections and rise in the number of immune-compromised individuals. The major factors positively impacting the growth of this market are fast paced advancements in developing diagnostic tests, focus on the development of novel and highly specific therapeutic molecules, and focus on the development of targeted therapies to curb systemic fungal infections. However, the protection of the drugs from generic erosion, reach and efficiency of the therapeutics, and emergence of local players may mask the growth of the market.
Transparency Market Research
90 State Street,
NY – 12207
USA – Canada Toll Free 866-552-3453